These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 15161438

  • 1. Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction.
    Piazza F, Semenzato G.
    Expert Rev Anticancer Ther; 2004 Jun; 4(3):387-400. PubMed ID: 15161438
    [Abstract] [Full Text] [Related]

  • 2. Acute myeloid leukemia: therapeutic impact of epigenetic drugs.
    Altucci L, Clarke N, Nebbioso A, Scognamiglio A, Gronemeyer H.
    Int J Biochem Cell Biol; 2005 Sep; 37(9):1752-62. PubMed ID: 15964234
    [Abstract] [Full Text] [Related]

  • 3. Novel agents in acute myeloid leukemia.
    Aribi A, Ravandi F, Giles F.
    Cancer J; 2006 Sep; 12(2):77-91. PubMed ID: 16630396
    [Abstract] [Full Text] [Related]

  • 4. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia.
    Doepfner KT, Boller D, Arcaro A.
    Crit Rev Oncol Hematol; 2007 Sep; 63(3):215-30. PubMed ID: 17658267
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.
    Chase A, Cross NC.
    Clin Sci (Lond); 2006 Oct; 111(4):233-49. PubMed ID: 16961463
    [Abstract] [Full Text] [Related]

  • 9. Farnesyltransferase inhibitors (FTIs) in myeloid malignancies.
    Karp JE, Lancet JE.
    Ann Hematol; 2004 Oct; 83 Suppl 1():S87-8. PubMed ID: 15124688
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells.
    Muranyi AL, Dedhar S, Hogge DE.
    Exp Hematol; 2009 Apr; 37(4):450-60. PubMed ID: 19302919
    [Abstract] [Full Text] [Related]

  • 12. Retinoic acid receptors, hematopoiesis and leukemogenesis.
    Collins SJ.
    Curr Opin Hematol; 2008 Jul; 15(4):346-51. PubMed ID: 18536573
    [Abstract] [Full Text] [Related]

  • 13. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia.
    Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, Nanni M, Careddu A, Fazi F, Padula F, Fiorini R, Spiriti MA, Petti MC, Venditti A, Amadori S, Mandelli F, Pelicci PG, Nervi C.
    Cancer Res; 2006 Sep 01; 66(17):8903-11. PubMed ID: 16951208
    [Abstract] [Full Text] [Related]

  • 14. Molecularly targeted therapy in acute myeloid leukemia.
    Bernasconi P, Boni M, Cavigliano PM, Calatroni S, Giardini I, Rocca B, Zappatore R, Caresana M, Quarna J.
    Ann N Y Acad Sci; 2004 Dec 01; 1028():409-22. PubMed ID: 15650266
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Molecular hemato-oncology and new specific treatment strategies for leukemia].
    Martínez-Mancilla M, Zafra-de la Rosa G, Reynoso-Gómez E, Astudillo-de la Vega H, Nambo-Lucio Mde J, Benítez-Bribiesca L, Martínez-Avalos A, Rivera-Luna R, Gariglio P.
    Gac Med Mex; 2006 Dec 01; 142(2):145-50. PubMed ID: 16711549
    [Abstract] [Full Text] [Related]

  • 18. Treatment of childhood acute myeloid leukemia.
    ter Bals E, Kaspers GJ.
    Expert Rev Anticancer Ther; 2005 Oct 01; 5(5):917-29. PubMed ID: 16221060
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.